Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Spironolactone  COVID-19 treatment studies for Spironolactone  C19 studies: Spironolactone  Spironolactone   Select treatmentSelect treatmentTreatmentsTreatments
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta
Lactoferrin Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent: 
0 0.5 1 1.5 2+ Ventilation 69% Improvement Relative Risk ICU admission 58% c19early.org/sp Cousins et al. Spironolactone for COVID-19 Prophylaxis Favors spironolactone Favors control
Integrative analysis of viral entry networks and clinical outcomes identifies a protective role for spironolactone in severe COVID-19
Cousins et al., medRxiv, doi:10.1101/2022.07.02.22277181 (Preprint)
6 Jul 2022    Source   PDF   Share   Tweet
PSM retrospective 64,349 COVID-19 patients in the USA, showing spironolactone associated with lower ICU admission.
Authors also present In Vitro research showing dose-dependent inhibition in a human lung epithelial cell line.
risk of mechanical ventilation, 69.0% lower, OR 0.31, p = 0.05, treatment 794, control 794, propensity score matching, RR approximated with OR.
risk of ICU admission, 58.0% lower, OR 0.42, p = 0.004, treatment 794, control 794, propensity score matching, RR approximated with OR.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Cousins et al., 6 Jul 2022, retrospective, USA, preprint, 8 authors.
Contact: cousinsh@stanford.edu, russ.altman@stanford.edu, yuan.luo@northwestern.edu, congle@stanford.edu.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperSpironolactoneAll
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit